Reuters logo
BRIEF-Zogenix Inc says European Commission designated ZX008 as an orphan medicinal product
March 1, 2017 / 11:34 AM / 9 months ago

BRIEF-Zogenix Inc says European Commission designated ZX008 as an orphan medicinal product

March 1 (Reuters) - Zogenix Inc

* Zogenix Inc - on March 1, 2017, co announced that european commission has designated zx008 (fenfluramine) as an orphan medicinal product-sec filing

* Zogenix Inc - ZX008 as an orphan medicinal product for treatment of lennox gastaut syndrome a refractory, debilitating childhood-onset epilepsy

* Zogenix Inc - company is currently enrolling patients in U.S. And internationally for a zx008 phase 3 program in dravet syndrome Source text for Eikon: (bit.ly/2mK0B8V) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below